Novartis partner Ophthotech says wet-AMD drug Fovista goes 0-for-3 in PhIII
Ophthotech’s lead drug is now a three-time loser in Phase III.
The biotech $OPHT had already largely written off the anti-PDGF Fovista after it failed the first two pivotal trials late last year, which triggered a company-wide reorganization and deep job cuts. But in case anyone was holding out hope that the drug might still show some signs of efficacy, the biotech reported that their drug combined with either Eylea or Avastin barely edged out either of the two standard anti-VEGFs alone in treating wet, age-related macular degeneration.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
